Fig. 5

Effect of G-CSF therapy on Bcl- 2 and Bax expression in BCAO mice. a Bcl-2 levels in the frontal (F _{(2, 9)} = 17.52, p = 0.0008) and middle (F _{(2, 9)} = 22.5, p = 0.0003) region of brain on day 4 and, Bax levels in the frontal (F _{(2, 9)} = 19.01, p = 0.0006) and middle (F _{(2, 9)} = 29.96, p = 0.0001) region of brain on day 4. b Bcl-2 levels in the frontal (F _{(2, 27)} = 4.571, p = 0.0195) and middle (F _{(2, 28)} = 5.352, p = 0.0108) region of brain on day 7. And, Bax levels in the frontal (F _{(2, 16)} = 7.959, p = 0.0040) and middle (F _{(2, 26)} = 5.817, p = 0.0082) region of brain on day 7. c Bcl-2/Bax ratio expression in the frontal (F _{(2, 9)} = 54.70, p < 0.0001) and middle (F _{(2, 9)} = 42.32, p < 0.0001) region of brain on day 4. d Bcl-2/Bax ratio expression in the frontal (F _{(2, 16)} = 114.6, p < 0.0001) and middle (F _{(2, 27)} = 43.12, p < 0.0001) region of brain on day 7. Representative western blots are presented with cropped blot panels showing target protein signals and control (GAPDH) protein signals in separate panels derived from the same gel. Graphs show mean ± SEM. * and # significant compared to sham & vehicle treated groups, respectively by ANOVA and Tukey post hoc tests (n = 5, p < 0.05)